Measurement of HDL-cholesterol is important in the risk evaluation of cardiovascular disease. Recently, we encountered a 61-year-old man with a negative result for HDLcholesterol using the Roche assay. Further analysis revealed that this patient had a monoclonal Ig type IgMk, with an electrophoresis-based concentration of 55.8 g/L, which apparently caused the negative result for HDL-cholesterol. Analysis of serum samples from other patients with monoclonal or polyclonal hypergammaglobulinaemia revealed that false negative results in the Roche assay for HDL-cholesterol may occur incidentally. Since negative results are detected easily in the laboratory, such patients do not pose a problem in daily practice. However, it is reasonable to suppose that false low results could also be caused by monoclonal as well as polyclonal Igs. Since such false low results remain undetected, vascular risk estimates consequently are altered and unnecessary treatment might be started. Ann Clin Biochem 2003; 40: 572-575 572
Introduction
Measuring HDL-cholesterol is important in evaluation of the risk of developing vascular occlusive disease. A variety of methods for measuring HDL-cholesterol are available, including ultracentrifugation, electrophoresis, precipitation-based methods and direct homogeneous assays. 1 At present, the more tedious methods for the determination of HDL-cholesterol, using a manual precipitation step followe d by measurement of the cholesterol content of the supernatant, 2^6 are being replaced by so-called homogeneous assays that directly measure cholesterol associated with the HDL particle, in automated analysers. 7^11 The major advantage of these direct assays is that manual precipitation steps are not necessary and there is less interference from native triglycerides. The method supplied by Roche (Roche GmbH, Mannheim, Germany) for their Hitachi/ Modular systems consists of a sequence of reactions using polyethyleneglycol (PEG)-modi¢ed enzymes that enhance the speci¢city towards HDL-cholesterol. 8 Furthermore, sulphated a-cyclodextrins are included, together with Mg 2+ to selectively block but not precipitate chylomicrons and VLDL, thereby providing selectivity without the need for clearing the sample mixture.
Recently, Roche introduced a new liquid reagent formulation for use in their Hitachi/Modular systems. In this modi¢ed reagent, the cyclodextrin was no longer included and the concentration of Mg 2+ was reduced. Here, we report a case in which a negative value for HDL-cholesterol using this Roche reagent initiated the detection of a monoclonal Ig. Further investigations revealed that negative results might be encountered in other monoclonal as well as polyclonal hypergammaglobulinaemias.
Methods
To obtain plasma or serum for analysis, we used plastic tubes with plasma (product no. 367994) or serum separator (product no. 367955) from Becton Dickinson (Rutherford NJ, USA). The plasma and serum preparation and the test analysis were performed using a Modular analyser (Roche) consisting of coupled preanalytic and analytic parts. The Roche reagents used for the various tests were: HDL-cholesterol plus second generation (product no. 304593); total cholesterol (CHOD-PAP, product no. 1491458); triglycerides (GPO-PAP, product no. 1730711); creatinine (Ja¡e¨, rate-blanked and compensated, product numbers 1875663 and 1929941); total protein (biuret, product no. 1929917); albumin (BCP, product no. 1815148); 
Case history
A 61-year-old man had been treated for 7 years by his family doctor for diabetes mellitus type II and hypertension with oral medication. He visited the outpatient department because of blurring of vision two weeks earlier. On fundoscopy, the ophthalmologist found sclerotic arteries and signs of veno-occlusion. Physical examination revealed a blood pressure of 170/ 90 mmHg in the left as well as the right arm, and murmurs were heard above the right carotic artery, above the left femoral artery and in the abdomen. The presumptive diagnosis of generalized atherosclerosis related to diabetes mellitus type II and hypertension was made. Results of the relevant laboratory tests are shown in Table 1 .
The negative result for HDL-cholesterol was con¢rmed by repeating and diluting the sample. Since the sample did not show any signs of lipaemia, icterus or haemolysis (no elevated results for the serum indexes and no visual turbidity), total protein and albumin were analysed because the sample seemed to be viscous. As a consequence of the elevated total protein concentration combined with a normal to low albumin, quantitative analysis of Ig, serum protein electrophoresis and immuno¢xation were performed. These results are also shown in Table 1 . Serum protein electrophoresis and immuno¢xation electrophoresis showed a monoclonal protein of Ig type Mk, with a concentration of 55.8 g/L based on protein electrophoresis and densitometry. Because of the monoclonal protein demonstrated in the serum of this patient, a haematological work-up was done. Cytological and immunological examination of the bone-marrow aspirate showed abnormalities typical of Walden-strÎm's macroglobulinaemia. Blood viscosity was elevated. After two sessions of plasmapheresis, laboratory investigations were repeated (results also shown in Table 1 ).
Additional investigations
The absorbance change during the reaction in the HDL-cholesterol assay is displayed in Fig. 1 together with the pattern obtained with a calibrator and control serum. This patient's serum displayed a high absorptivity in the pre-incubation part of the reaction, which was in contrast to the absorptivity for the calibrator and control sample. The most reasonable explanation for this high absorptivity would be precipitation of the monoclonal protein, which caused turbidity, increasing absorbance at the wavelength used for measurement of HDL-cholesterol. After adding the colouring reagent, the absorption decreased as a consequence of dilution (whereas in normal samples it would increase), thereby causing a negative result for HDL-cholesterol. In order to determine whether this negative result was just an isolated incident or not, we analysed HDLcholesterol in the serum of 15 other patients with monoclonal and polyclonal hypergammaglobulinaemia. Amongst these, we found two additional patients in whose serum a negative result for HDL-cholesterol was found. One of these patients, a 54-year-old man with a 5-year history of multiple myeloma, had a monoclonal IgGk of 25.1 g/L by protein electrophoresis and densitometry (quantitative IgG 35.5 g/L). The other patient, a 16-year-old human immunode¢ciency virus-positive girl, had a polyclonal hypergammaglobulinaemia of 78.8 g/L by protein electrophoresis and densitometry (quantitative IgG 83.3 g/L). The reaction pattern of the HDL-cholesterol in the three patients was compared with the pattern obtained for the calibrator and control sample (see Fig. 1 ). The pattern showed that an alternative calculation based on the absorbance di¡erence between the 5th min (just before starting the reaction by adding the colouring reagent) and the 10th min could not be used for the estimation of HDL-cholesterol in these patients, since all three patients showed a decrease of absorption after addition of the colouring reagent.
In another two patients, the absorption pattern showed reactivity in the pre-incubation part of the reaction and a decline after adding the colouring reagent, followed by an apparently normal absorption pattern. The decline directly after adding the colouring reagent led us to presume that the results for HDL-cholesterol in these patients might be falsely low. So far, because of an insu¤cient amount of sample, we have been unable to con¢rm these ¢ndings against the HDL-cholesterol reference method or the HDLcholesterol designated comparison method from the Centers of Disease Control, both being internationally recognized accuracy standards for HDL-cholesterol measurements. 12^14
Discussion
In the evaluation of the risk of developing vascular occlusive disease, an accurate measurement of HDLcholesterol is important. Since patients with monoclonal proteins sometimes present with symptoms of arterial or venous occlusion, HDL-cholesterol might be measured in such patients as a consequence of cardiovascular risk evaluation. For such a patient, when a negative result for HDL-cholesterol is detected in the laboratory, no result will be reported, or other tests (e.g. estimation of HDL-cholesterol using a precipitation method) might be undertaken to yield a reliable result. In both cases, no false conclusions will be made and unnecessary treatment will not be started. However, when the absorption patterns in the pre-incubation part of the assay show any reactivity, it might be argued that in the serum of patients with monoclonal proteins the occurrence of false low results for HDL-cholesterol could be possible.
Recently, the occurrence of such false low results in patients with monoclonal proteins was published for the Roche HDL-C Plus assay. 15 In contrast to the negative results for HDL-cholesterol, such false low results will be overlooked, even in the cases of patients with a known monoclonal Ig, and unnecessary treatment could be the ultimate consequence. Our patient may be an example of such a case. Looking at his results for HDL-cholesterol, the low and declining value in the previous 6 months (using the Roche HDL-C Plus assay) led us to conclude that these results were already falsely low as a consequence of the ongoing increase in monoclonal protein. However, since serum or plasma from that time was no longer available at the time of study, this hypothesis could not be proven. Since the introduction of discrete chemistry analysers instead of autoanalysers, possible interference of monoclonal proteins has became a well known phenomenon and has been described for various tests, including the HDL-cholesterol assay. 15^20 According to the manufacturer's package insert, which states:
. . . in rare cases increased Ig concentrations can lead to falsely increased HDL-cholesterol results', Roche was aware of a positive interference of Igs. A negative interference of monoclonal and polyclonal Igs in the second generation Roche assay for HDL-cholesterol had not been encountered before.
In conclusion, this case illustrates that unlikely results for laboratory tests need further evaluation and that such results might be a clue to an unexpected diagnosis. Furthermore, in patients with known monoclonal as well as polyclonal hypergammaglobulinaemia, results for HDL-cholesterol by direct methods should be interpreted with care since such results might be falsely low due to Ig interference.
